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Abstract
Background: There are limited data regarding the predictors of mortality in patients with 
acute congestive heart failure (CHF) and left ventricular ejection fraction (LVEF) ≥ 40%.
Methods: We evaluated clinical characteristics, mortality and prognostic factors in a sample 
of consecutive patients hospitalized for CHF with LVEF ≥ 40%. Multivariable Cox regression 
models were developed to predict mortality using baseline clinical characteristics and echocar-
diographic variables.
Results: The study population consisted of 191 patients, mean age 70 ± 14.6 years (60% fe-
male) with average follow-up of 4.0 ± 2.8 years. Cumulative 5-year mortality was 58% in the 
entire population and it was 59% in men and 57% in women (p = 0.411). In multivariable 
analyses, predictors of mortality were the following: blood urea nitrogen (BUN) > 25 mg/dL  
(HR = 1.77; p = 0.002); absence of hypertension (HR = 1.58; p = 0.032), left ventricular 
end diastolic dimension (LVEDD) ≤ 4.1 cm (HR = 1.73; p = 0.011) and LVEF ≤ 45%  
(HR = 1.69; p = 0.027).
Conclusions: Patients hospitalized for heart failure with LVEF ≥ 40% have very high mortal-
ity. Absence of hypertension, elevated BUN and lower LVEF ≤ 45% indicate increased risk of 
short- and long-term mortality. Lower LVEDD is an independent predictor of mortality in heart 
failure patients with LVEF ≥ 40%. (Cardiol J 2015; 22, 4: 382–390)
Key words: heart failure, left ventricular dimension, heart failure with  
preserved ejection fraction, hypertension
Introduction
Heart failure (HF) with preserved ejection 
fraction (HFpEF) is currently observed in 50% 
of all HF patients [1, 2]. The incidence of HFpEF 
increases with age with higher prevalence among 
women and the most common underlying etiol-
ogy is hypertensive heart disease [3–5]. This is 
in contrast to HF with reduced ejection fraction 
(HFrEF) which is more prevalent among men and 
more often due to ischemic heart disease. The 
prevalence of HFpEF is rising with a rate of 1% 
per year with no improvement in outcomes when 
compared with patients with HFrEF [1]. Despite 
significant advances in the treatment of congestive 
heart failure (CHF), short- and long-term mortality 
remains very high. Morbidity and mortality in HF-
pEF are also similar to values observed in patients 
with HFrEF [3]. The mortality burden of HFpEF is 
substantial, ranging from 10% to 30% annually and 
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higher in epidemiological studies than in clinical 
trials [6]. The aim of this study was to evaluate the 
clinical characteristics, long-term mortality and to 
identify prognostic factors in patients hospitalized 
for acute CHF with left ventricular ejection fraction 
(LVEF) ≥ 40%.
Methods
Study population
Medical records of consecutive sample of pa-
tients hospitalized at the University of Rochester 
Medical Center for decompensated HF between 
January 1st 2003 to May 30th 2003 with LVEF ≥ 40% 
were evaluated. Patients were identified using 
International Classification of Diseases, Ninth revi-
sion (ICD9) codes specific for CHF (428.0–428.9) 
with documented LVEF in the hospital system. The 
index date was assigned at the first qualifying hos-
pitalization. A detailed review of electronic medical 
records was carried out to confirm the presentation 
of decompensated CHF. Clinical demographics and 
baseline clinical data including history of hyperten-
sion, hyperlipidemia, coronary artery disease, prior 
history of percutaneous coronary intervention or 
coronary artery bypass graft, diabetes mellitus, and 
atrial fibrillation (AF) were collected by reviewing 
the electronic medical records. The electrocardio-
graphic parameters recorded were rate, rhythm, 
QRS duration, QTc interval, and presence of bundle 
branch blocks. Use of following medications was 
recorded: diuretics, beta-blockers, angiotensin 
converting enzyme inhibitors, angiotensin recep-
tor blocking agents, calcium channel blockers, and 
digoxin. The laboratory data collected were serum 
potassium, creatinine, blood urea nitrogen (BUN) 
and glomerular filtration rate (GFR), calculated us-
ing Modification of Diet in Renal Disease equation.
Echocardiographic variables
The echocardiographic variables were re-
trieved using the hospital electronic database 
for echocardiograms including: LVEF (%), septal 
and lateral wall thickness, left atrial diameter, 
left ventricular end systolic diameter (LVESD), 
left ventricular end diastolic diameter (LVEDD), 
pulmonary artery systolic pressure, and left ven-
tricular mass (LVM). All echocardiograms were 
performed using the American Society of Echo-
cardiography guidelines.
Endpoints
The primary end point for this study was all-
cause mortality. Mortality data were obtained from 
Social Security Death Index. The analyses were 
performed to predict 1-, 3-, and 5-year mortal-
ity. The study was approved by the Institutional 
Review Board.
Statistical analyses
Continuous variables were presented as means 
and standard deviation while categorical variables 
were presented as percentages. Comparison of 
baseline characteristics by mortality status (dead 
vs. alive) was performed with a t-test for continuous 
variables and c2 test for categorical variables. The 
Cox proportional hazards model with best subset 
regression was used to determine which clinical 
and echocardiographic measurements were signifi-
cantly related to mortality during follow-up of the 
study. For all echocardiographic variables, patients 
were divided into quartiles for analyses. For LVEF, 
a pre-specified cutoff point of 45% was used in the 
analyses. Where appropriate, Kaplan-Meier cumula-
tive mortality curves were plotted to display trends 
in mortality over time. All statistical analyses were 
performed using SAS 9.2 soft ware. A p value < 0.05 
was considered statistically significant.
Results
Patient characteristics and follow-up
There were 200 patients identified from the 
medical records with CHF hospitalization and docu-
mented LVEF ≥ 40%. Nine patients were excluded 
based on findings of moderate to severe valvular 
disease. Study population was 191 with mean age 
70 ± 14.6 years, 115 (60%) female with a mean 
follow-up of 4.0 ± 2.8 years. The mean LVEF for 
the cohort was 54 ± 7.4%. One hundred and forty-
five (76%) patients were white. Hypertension was 
present in 140 (74%), coronary artery disease in 95 
(50%), diabetes in 83 (43.7%) and AF in 59 (31%) 
patients (Table 1).
Mortality
There were 129 deaths during the follow-up 
of 4.0 ± 2.8 years. Patients who died in the study 
follow-up, were older (72.2 ± 13.5 vs. 66.0 ± 15.8, 
p = 0.010), had higher BUN [mg/dL] (34.7 ± 21.3 
vs. 28.3 ± 21.9, p = 0.017) and a trend towards 
more AF (35% vs. 23%, p = 0.09). There were no 
differences in other clinical characteristics, labora-
tory data and use of medications between patients 
who died vs. alive (Table 1).
The cumulative 1-year mortality was 25%, 
3-year mortality was 41%, and 5-year mortality was 
58% (Fig. 1). As shown in Figure 2, there was no 
www.cardiologyjournal.org 383
Saadia Sherazi et al., Heart failure with preserved ejection fraction and mortality
difference in mortality between men and women 
(p = 0.411). Cumulative mortality among patients 
with history of hypertension vs. no history of hy-
pertension and patients with BUN > 25 mg/dL vs. 
BUN ≤ 25 mg/dL is shown in Figures 3A and 3B, 
respetively. There was no difference in mortality 
Table 1. Baseline clinical characteristics of 191 patients hospitalized for heart failure with left ventricular 
ejection fraction ≥ 40%.
Variable Overall (n = 191) Alive (n = 62) Dead (n = 129) P 
Age [years] 70.2 ± 14.6 66.0 ± 15.8 72.2 ± 13.5 0.010
Female 115 (60.2%) 40 (64.5%) 75 (58.1%) 0.399
Caucasian 145 (75.9%) 44 (71.0%) 101 (78.3%) 0.268
Systolic blood pressure [mm Hg] 138 ± 30.7 138.9 ± 30.7 134.9 ± 30.7 0.719
Diastolic blood pressure [mm Hg] 70.0 ± 18.9 73.2 ± 17.9 68.6 ± 19.2 0.160
Hypertension 138 (73.4%) 47 (77.0%) 91 (71.7%) 0.433
Diabetes mellitus 89 (43.7%) 26 (42.6%) 63 (49.6%) 0.369
Atrial fibrillation 59 (31.1 %) 14 (23.0%) 45 (34.9%) 0.097
Coronary artery disease 94 (49.5%) 26 (42.6%) 68 (52.7%) 0.194
Hyperlipidemia 62 (33.3%) 25 (41.0%) 37 (29.6%) 0.122
Creatinine [mg/dL] 2.2 ± 2.7 2.4 ± 3.3 2.08 ± 2.4 0.652
Blood urea nitrogen 32.7 ± 21.6 28.3 ± 21.9 34.7 ± 21.3 0.017
Glomerular filtration rate 54.9 ± 36.7 56.2 ± 36.7 54.3 ± 36.8 0.601
QTc 433.4 ± 51.3 431.6 ± 67.1 434 ± 42.6 0.793
QRS 97.9 ± 24.8 94.7 ± 20.5 99.3 ± 26.4 0.569
ACE-I/ARB 105 (57.1%) 38 (64.4%) 67 (53.3%) 0.167
Beta blockers 125 (67.9%) 43 (72.9%) 82 (65.6%) 0.323
Calcium channel blockers 52 (28.1%) 15 (25.4%) 37 (29.4%) 0.578
Diuretic 166 (89.7%) 53 (89.8%) 113 (89.7%) 0.975
Digoxin 32 (17.3%) 7 (11.9%) 25 (19.8%) 0.181
Statins 83 (45.6%) 32 (54.2%) 51 (41.5%) 0.105
Values are given as percentages or means ± standard deviation; ACE-I — angiotensin converting enzyme inhibitor; ARB — angiotensin  
receptor blocker
Figure 1. Cumulative 1-year mortality was 25%, 3-year mortality was 41% and 5-year mortality was 58%.
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among patients with LVEF ≤ 45% and LVEF > 45% 
(Fig. 4A, p = 0.402). For all the echocardiographic 
variables presented in Table 2, quartile distribution 
was examined and provided basis for grouping of 
values in dichotomous fashion comparing lower 
quartile (Q1) with upper quartiles (Q2–Q4). Among 
all of the echocardiographic variables, LVEDD 
lower quartile ≤ 4.1 cm compared with > 4.1 cm 
was the only significant variable that was associ-
ated with mortality. Mortalilty among quartiles of 
LVEDD and cumulative mortality among patients 
in Q1 of LVEDD (≤ 4.1 cm) vs. Q2–Q4 (> 4.1 cm) 
is shown in Figures 4B and 4C, respectively.
In multivariable Cox regression, predictors of 
mortality for the entire follow-up (4.0 ± 2.8 years) 
were: BUN > 25 mg/dL (HR = 1.77, p = 0.002), 
absence of hypertension (HR = 1.61, p = 0.022), 
LVEF ≤ 45% (HR = 1.69, p = 0.027), and LVEDD 
≤ 4.1 cm (HR = 1.59, p = 0.026). At 1 year, the 
predictors of mortality were: BUN > 25 mg/dL 
(HR = 2.65, p = 0.005), absence of hyper- 
tension (HR 2.30, p = 0.01) and LVEDD ≤ 4.1 cm 
(HR = 1.70, p = 0.12) (Table 3). Separate analysis 
evaluating the risk of mortality, defined as 3-year 
and 5-year yielded similar results. There was no 
significant difference in LVM or LV wall thickness 
between patients with LVEDD > 4.1 vs. ≤ 4.1 cm.
Discussion
Our study confirms that patients admitted with 
HF with a relatively preserved LVEF are at very high 
risk for short- and long-term mortality. Few studies 
have explored the prognostic factors that influence 
outcomes in this group of patients. Absence of hyper-
tension, BUN > 25 mg/dL, LVEF ≤ 45% and lower 
LVEDD were identified as important prognostic vari-
ables predicting mortality. In addition, the observed 
high mortality rate was independent of gender.
Hypertension is one of the major risk factors 
for development of diastolic dysfunction and sub-
sequently HF. There is convincing data to support 
the statement that adequate control of hyperten-
sion decreases the incidence of new onset HF ir-
respective of the type of anti-hypertensive therapy 
administered [7]. Hypertension was reported in 
74% of our study cohort, which is similar to the 
prevalence of hypertension in HFpEF reported 
in the literature. A recent study evaluated sex 
differences in baseline characteristics and out-
comes in 4,128 patients enrolled in Irbesartan in 
Heart Failure with Preserved Ejection Fraction 
(I-PRESERVE) trial [8]. Hypertension was as-
sociated with a lower all-cause mortality (HR = 
= 0.845) among women, however the p value did not 
reach statistical significance (0.138). Overall better 
prognosis seen in patients with hypertension could 
be explained by several mechanisms. Underlying 
etiologic mechanisms leading to diastolic HF other 
than hypertension, for example coronary artery 
disease and diabetes mellitus might be one of the 
reasons leading to higher mortality. As shown in 
a study by O’Connor et al. [9], the coronary artery 
disease index and diabetes mellitus were associated 
Figure 2. Cumulative mortality by gender in patients with left ventricular ejection fraction ≥ 40%.
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with increased mortality in patients with HF and 
LVEF > 45%. Furthermore, anti-hypertensive 
therapy for patients with hypertension may have 
resulted in the observed protective effect [7].
The association between abnormal renal func-
tion and increased risk of death and hospitalization 
in HF patients has previously been reported [10, 11]. 
A post-hoc analysis of the Digitalis Investiga-
tion Group (DIG) trial demonstrated increasing 
mortality with decreasing quartile of creatinine 
clearance and 6-min walking distance < 262 m 
[12]. Similarly, a post-hoc analysis of the Studies 
Of Left Ventricular Dysfunction (SOLVD) registry 
demonstrated worse combined outcome of hospi-
talization or death for the subset of patients with 
creatinine clearance < 60 mL/min [13]. Impaired 
renal function represents advanced underlying HF 
and systemic disease whether it is hypertension, 
diabetes, or vascular disease resulting in high risk 
of mortality.
LVEF is a widely used clinical measure to as-
sess left ventricular function and has been shown 
to predict mortality in HF patients with low ejec-
tion fraction (EF) [14]. The relationship between 
a wide range of LVEF and both fatal and non-fatal 
outcomes was assessed in 7,599 patients enrolled 
Figure 3. Cumulative mortality in patients with history of hypertension vs. no history of hypertension (A) and in 
patients with blood urea nitrogen (BUN) > 25 mg/dL vs. BUN ≤ 25 mg/dL (B).
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Figure 4. Cumulative mortality in patients with left ventricular ejection fraction (LVEF) > 45% vs. ≤ 36–45% (A), pa-
tients in quartiles of left ventricular end diastolic dimension (LVEDD) (B), and patients in quartile (QTR) 1 (≤ 4.1 cm) vs. 
quartiles (QTR) 2–4 (> 4.1 cm) of LVEDD (C).
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in the CHARM (Candesartan in Heart Failure- 
-Assessment of Reduction in Mortality) study 
population [15]. The mean LVEF was 38.8 ± 14.9%. 
The study concluded that LVEF predicts mortal-
ity with overall better survival in patients with 
increasing EF up to 45%. For each 10% reduction 
in the EF below 45%, the risk for total mortality 
increased by up to 39%.
The role of left ventricle cavity size as a pro- 
gnostic factor is well studied in patients with 
systolic HF. In a small sample of 50 patients with 
CHF with mean LVEF 32%, LVEDD (6.1 cm) 
was not associated with increased mortality [16]. 
However, in the same study, the LVESD (4.7 cm) 
was significantly associated with higher mortality. 
In this study, patients with preserved LVEF were 
Table 3. Cox regression models for entire follow-up, 1-year, 3-year, and 5-year.
Parameter Hazard ratio 95% hazard ratio confidence limits P 
For entire follow-up 
BUN > 25 mg/dL 1.79 1.22–2.61 0.002
Absence of hypertension 1.58 1.03–2.42 0.032
LVEDD < 4.1 cm 1.73 1.13–2.65 0.011
LVEF £ 45% 1.69 1.06–2.72 0.027
One-year mortality
BUN > 25 mg/dL 2.69 1.34–5.38 0.005
Absence of hypertension 2.23 1.14–4.37 0.018
LVEDD < 4.1 cm 1.82 0.91–3.64 0.086
LVEF £ 45% 1.65 0.74–3.69 0.217
3-year mortality
BUN > 25 mg/dL 1.97 1.21–3.22 0.006
Absence of hypertension 1.60 0.95–2.69 0.075
LVEDD < 4.1 cm 2.30 1.37–3.87 0.001
LVEF £ 45% 2.05 1.14–3.67 0.015
5-year mortality
BUN > 25 mg/dL 1.95 1.29–2.95 0.001
Absence of hypertension 1.75 1.30–2.73 0.012
LVEDD < 4.1 cm 2.03 1.29–3.17 0.001
LVEF ≤ 45% 1.77 1.06–2.94 0.027
The following variables were entered in the model: atrial fibrillation, age > 75 years, BUN > 25, history of coronary artery bypass grafting, 
history of coronary artery disease, hypertension, hyperlipidemia, hematocrit, LVEDD, LVEDD (high risk quartile), LVEF > 50%, LVEF < 45%, 
LVEDD < 4.1 cm; BUN — blood urea nitrogen; LVEDD — left ventricular end diastolic dimension; LVEF — left ventricular ejection fraction
Table 2. Echocardiographic parameters by mortality status.
Echocardiographic parameters Overall (n = 191) Alive (n = 62) Dead (n = 129) P
LVEF [%] 54.6 ± 7.4 54.7 ± 6.8 54.6 ± 7.7 0.976
LVEF < 45% 18.3% 16.1% 19.4% 0.587
LVEDD [cm] 4.6 ± 0.7 4.7 ± 0.7 4.6 ± 0.7 0.163
LVEDD < 4.1 [cm] 25.9% 21.1% 28.2% 0.312
Left atrial diameter [cm] 4.3 ± 0.7 4.3 ± 0.7 4.4 ± 0.6 0.674
Left ventricular mass 142.9 ± 45.2 148.8±49.2 139.9 ± 43 0.376
Posterior wall thickness [cm] 1.2 ± 0.2 1.2 ± 0.3 1.2 ± 0.2 0.084
Septal wall thickness [cm] 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 0.529
PASP [mm Hg] 45.7 ± 13.6 44.61 ± 2.7 46.3 ± 14.1 0.542
LVEDD — left ventricular end diastolic dimension; LVEF — left ventricular ejection fraction; PASP — pulmonary artery systolic pressure
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excluded. In our study, a smaller left ventricular cav-
ity size ≤ 4.1 cm is associated with worse prognosis. 
Little is known regarding the prognostic significance 
of small cavity in HFpEF population. It is well de-
scribed in the literature that patients with HFpEF 
have significant abnormalities in active relaxation 
and passive stiffness and generally have normal 
or even small left ventricular chamber volumes 
[17]. Due to increased passive stiffness of the left 
ventricle, significant changes in pressure may be 
seen even with little or no detectable change in ven-
tricular volume [18]. Smaller cavity in HFpEF likely 
represents increased passive chamber stiffness; 
the ventricle is unable to accept venous return ad-
equately without high diastolic pressures. Such high 
filling pressures result in worsening HF symptoms 
and increase mortality. Further studies are needed 
to evaluate the relationship between LVEDD and 
passive stiffness in patients with HFpEF.
We did not find age and AF as significant pre-
dictors of mortality independent of other covari-
ates. This could be a result of small sample size. 
Other studies have shown age as one of the sig-
nificant determinants of prognosis in patients with 
HFpEF [19]. The approximate 5-year mortality in 
patients with HFpEF rises with increasing age from 
15% in patients < 50 years to 33% in patients with 
age 50–70 years and approaching 50% in patients 
> 70 years old [19]. In our study, patients were 
relatively older (70.2 ± 14.6) and influence of age 
on mortality could not be demonstrated. AF is 
common among patients with HFpEF and it was 
reported in 31% patients in our study. CHARM 
sub-group analysis showed that patients with AF 
and preserved LVEF had higher risk for adverse 
cardiovascular outcome (34% with cardiovascular 
death or CHF hospitalization) relative to those 
with preserved LVEF and sinus rhythm (21%) 
[20]. After covariate adjustment, AF at baseline 
remained an independent predictor of all-cause 
mortality regardless of baseline LVEF. However, 
another report showed that AF was associated 
with an excessive mortality mainly related to the 
advanced age [21]. An explanation for variable 
results regarding prognostic significance of AF in 
HFpEF might be due to the differences in the study 
population. Alternatively, loss of atrial kick during 
AF may result in different hemodynamic effects 
among the patients with LVEF > 50% as compared 
with those with slightly reduced LVEF 40–50%.
Limitations of the study
Our study has limitations, including the ret-
rospective design and the small study cohort. We 
also lacked detailed systematic examination of the 
diastolic dysfunction in each patient and biomark-
ers such as troponin and B-type natriuretic peptide 
level. Neither the data on revascularization during 
the index hospitalization were analyzed. Further 
studies involving larger patient populations with 
detailed information on diastolic dysfunction are 
required to elucidate the validity of our clinical 
findings.
Conclusions
Mortality among patients hospitalized for HF 
with LVEF ≥ 40% remains very high. Prognosis of pa-
tients hospitalized for HF with LVEF ≤ 45% is as poor 
as the prognosis of HF patients with LVEF > 45%. 
Absence of hypertension and elevated BUN indi-
cate increased risk of short- and long-term mortal-
ity. Patients hospitalized for HF with absence of 
hypertension need special care to improve their 
outcomes. LVEDD is found to be an independent 
predictor of mortality in HF patients with LVEF 
≥ 40%. A lower LVEDD may represent a “stiff” 
ventricle with compromised diastolic heart function.
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